Antengene gets NMPA nod for eltanexor phase 1/2 clinical trial in myelodysplastic syndrome

Antengene has been given approval from China’s National Medical Products Administration (NMPA) for a phase 1/2 clinical trial of ATG-016 (eltanexor) in myelodysplastic syndrome (MDS). ... Read More